Sienna™ COVID-19 Rapid Antigen Test
The Sienna Covid-19 rapid antigen test is authorized for professional use by the FDA (EUA) in point-of-care settings by organizations with CLIA certification.
With visual results in 10 minutes and nasopharyngeal collection, Sienna is fast and accurate.
Contact us for pricing and delivery.
The Sienna Covid-19 rapid antigen test is authorized for professional use by the FDA (EUA) in point-of-care settings by organizations with CLIA certification.
With visual results in 10 minutes and nasopharyngeal collection, Sienna is fast and accurate.
Contact us for pricing and delivery.
The Sienna Covid-19 rapid antigen test is authorized for professional use by the FDA (EUA) in point-of-care settings by organizations with CLIA certification.
With visual results in 10 minutes and nasopharyngeal collection, Sienna is fast and accurate.
Contact us for pricing and delivery.
General Details
Test type: Antigen
Run time: 10-20 minutes
Collection type: Nasopharyngeal swab
Authorization: FDA EUA for professional use. CLIA required.
Intended Use: Lateral flow immunoassay intended for the qualitative detection of SARS-CoV-2 nucleocapsid protein.
Manufacturer: Salofa Oy (Finland)
Clinical Details
SARS-CoV-2: 93.8% Sensitivity, 99.2% Specificity
Specificity: No cross-reaction with species tested
Interference: No interfering factors tested
CPT Codes: Covid-19 87811QW
Box Components
Nasopharyngeal swabs (25)
Test cassettes (25)
Extraction reagent capsules (25)
Workstation for mass testing (1)
Instructions for use (1)
Storage and Handling
Test kits should be stored at 2-30°C (35-86°F). Reagents and materials are stable until the expiration date printed on the outer packaging. Do not use beyond the expiration date. The test device must remain in the sealed pouch until use. Do not freeze any contents of the kit.
Intended Use
The Sienna COVID-19 Antigen Rapid Test Cassette is a rapid chromatographic immunoassay for the qualitative detection of COVID-19 antigen in Nasopharyngeal swab. The identification is based on the monoclonal antibodies specific for the Nucleocapsid protein of SARS-CoV-2. It is intended to aid in the rapid diagnosis of COVID-19 infections.